2009-2021 年德国恶性胰腺神经内分泌肿瘤患者的发病率和生存率。

Incidence and survival of patients with malignant pancreatic neuroendocrine neoplasms in Germany, 2009-2021.

机构信息

Institute of Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Germany; School of Public Health, Department of Epidemiology, Boston University, Boston, USA; Cancer Registry of North Rhine-Westphalia, Bochum, Germany.

Cancer Registry of North Rhine-Westphalia, Bochum, Germany.

出版信息

Cancer Epidemiol. 2024 Dec;93:102659. doi: 10.1016/j.canep.2024.102659. Epub 2024 Sep 6.

DOI:10.1016/j.canep.2024.102659

PMID:39243580

Abstract

BACKGROUND

Due to the rarity of pancreatic neuroendocrine neoplasms, only few population-representative studies on incidence and survival have been conducted. The aim was to provide up-to-date nationwide incidence and relative survival estimates of neuroendocrine (NE) neoplasms overall, NE tumors (NETs), NE carcinomas (NECs), and mixed NE neoplasms (MiNEN).

METHODS

We distinguished between pancreatic NETs (functioning versus non-functioning), NECs and mixed NE neoplasms and analyzed data from 2009 through 2021 from all German cancer registries covering a population of more than 80 million. We calculated crude and age-standardized incidence rates and 5-year relative survival estimates (RS).

RESULTS

Overall 6474, 4217, and 243 patients with pancreatic NETs, NECs, and mixed NE neoplasms, respectively were registered. While the age-standardized incidence of NETs has increased (+16.4 % per year, 95 %CI 12.2;20.7), the incidence of NEC has fallen (about -6.4 % per year, 95 %CI -8.0; -4.8). The crude RS was 77.7 % (standard error [SE] 0.9) for non-functioning NETs, 90.3 % for functioning NETs (SE 3.9), and 18.5 % (SE 3.9) for MiNEN. Large and small cell NECs had a low RS (9.1 % and 6.9 %, respectively). RS for G1 NETs was 88.2 %, while it was only 36.6 % for G3 NETs. Localized NETs had a RS of 92.8 %, while distant metastatic NETs had a RS of 45.0 %.

CONCLUSIONS

The incidence of pancreatic NETs has increased markedly in Germany in the period 2009-2021. Subgroups of NETs (G1 grading or localized stage) have an excellent prognosis. RS of MiNEN is more similar to NECs than NETs.

摘要

背景

由于胰腺神经内分泌肿瘤罕见，仅有少数基于人群的关于发病率和生存率的研究。本研究旨在提供最新的全国范围内神经内分泌（NE）肿瘤、NE 肿瘤（NETs）、NE 癌（NECs）和混合 NE 肿瘤（MiNEN）的发病率和相对生存率估计。

方法

我们区分了胰腺 NETs（功能性与非功能性）、NECs 和混合 NE 肿瘤，并分析了 2009 年至 2021 年期间来自覆盖 8000 多万人口的所有德国癌症登记处的数据。我们计算了粗发病率和年龄标准化发病率以及 5 年相对生存率（RS）。

结果

共登记了 6474 例胰腺 NETs、4217 例 NECs 和 243 例混合 NE 肿瘤患者。NETs 的年龄标准化发病率增加（每年增加 16.4%，95%CI 12.2%；20.7%），而 NEC 的发病率下降（每年下降约 6.4%，95%CI -8.0%；-4.8%）。非功能性 NETs 的粗 RS 为 77.7%（标准误差 [SE] 0.9），功能性 NETs 为 90.3%（SE 3.9），MiNEN 为 18.5%（SE 3.9）。大细胞和小细胞 NEC 的 RS 较低（分别为 9.1%和 6.9%）。G1 NETs 的 RS 为 88.2%，而 G3 NETs 的 RS 仅为 36.6%。局限性 NETs 的 RS 为 92.8%，而远处转移的 NETs 的 RS 为 45.0%。